PDCD1 and head and neck squamous cell carcinoma: Our findings suggest that patients lacking 11q13 amplification are more likely to exhibit a favorable response to anti-PD-1 therapy, indicating that 11q13 amplification status may inform clinical decision-making regarding the utilization of immunotherapy in HNSCC.